{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:23:10Z","timestamp":1794576190748,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jcyt.2026.102954","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:46:57Z","timestamp":1783529217000},"page":"102954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Haploidentical transplantation versus umbilical cord blood transplantation in acute myeloid leukemia with measurable residual disease"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7569-6888","authenticated-orcid":false,"given":"Masahiro","family":"Teramoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1018-9508","authenticated-orcid":false,"given":"Yoshimitsu","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-9775","authenticated-orcid":false,"given":"Masamitsu","family":"Yanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4405-8808","authenticated-orcid":false,"given":"Shohei","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4795-121X","authenticated-orcid":false,"given":"Koji","family":"Nagafuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4203-990X","authenticated-orcid":false,"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4896-5878","authenticated-orcid":false,"given":"Masao","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2630-493X","authenticated-orcid":false,"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0148-644X","authenticated-orcid":false,"given":"Toshihiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9653-6170","authenticated-orcid":false,"given":"Atsushi","family":"Wake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8814-230X","authenticated-orcid":false,"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-5926","authenticated-orcid":false,"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9925-2093","authenticated-orcid":false,"given":"Yuta","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1296-9006","authenticated-orcid":false,"given":"Masahito","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-9315","authenticated-orcid":false,"given":"Hideki","family":"Nakasone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7668-6083","authenticated-orcid":false,"given":"Fumihiko","family":"Ishimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1953-8463","authenticated-orcid":false,"given":"Takaaki","family":"Konuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102954_bib0001","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0002","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbmt.2017.09.001","article-title":"Bone marrow WT1 levels in allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplasia: clinically relevant time points and 100 copies threshold value","volume":"24","author":"Nomded\u00e9u","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102954_bib0003","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/ejh.70024","article-title":"Significance of pre- and posttransplant minimal residual disease on transplant outcomes in core-binding factor acute myeloid leukemia","volume":"115","author":"Tokuda","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0004","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0005","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102954_bib0006","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular Minimal Residual Disease in Acute Myeloid Leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102954_bib0007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102954_bib0008","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102954_bib0009","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","article-title":"The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT","volume":"60","author":"Passweg","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102954_bib0010","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102954_bib0011","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/bloodadvances.2019000050","article-title":"Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission","volume":"3","author":"Rashidi","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102954_bib0012","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/ajh.70008","volume":"100","author":"Ye","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0013","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ajh.25647","article-title":"Haploidentical transplantation for acute myeloid leukemia patients with minimal\/measurable residual disease at transplantation","volume":"94","author":"Srour","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0014","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102954_bib0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12185-019-02672-4","article-title":"Single cord blood transplantation in Japan; expanding the possibilities of CBT","volume":"110","author":"Yamamoto","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0016","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/bjh.70099","article-title":"Has early mortality following single-unit unrelated cord blood transplantation improved in recent years? A nationwide registry data analysis from 2003 to 2022 in Japan","volume":"207","author":"Konuma","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0017","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41375-021-01474-0","article-title":"Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia","volume":"36","author":"Shimomura","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102954_bib0018","doi-asserted-by":"crossref","first-page":"215.e1","DOI":"10.1016\/j.jtct.2023.12.002","volume":"30","author":"Konuma","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102954_bib0019","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41409-025-02729-5","article-title":"Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia","volume":"61","author":"Yanada","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102954_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, Part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","article-title":"Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation","volume":"103","author":"Kanda","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0022","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102954_bib0023","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102954_bib0024","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102954_bib0025","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/10428194.2017.1357173","article-title":"Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients","volume":"59","author":"Yanada","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jcyt.2026.102954_bib0026","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102954_bib0027","first-page":"250","article-title":"Chronic graft-versus-host disease and other late complications of bone marrow transplantation","volume":"28","author":"Sullivan","year":"1991","journal-title":"Semin Hematol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0028","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41409-018-0169-6","article-title":"Refined graft-versus-host disease\/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia","volume":"53","author":"Battipaglia","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102954_bib0029","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.bbmt.2018.01.002","article-title":"Blood and marrow transplant clinical trials network report on the development of novel endpoints and selection of promising approaches for graft-versus-host disease prevention trials","volume":"24","author":"Pasquini","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102954_bib0030","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102954_bib0031","first-page":"2954","article-title":"Measurable residual disease recurrence as early warning of relapse in acute myeloid leukemia","volume":"110","author":"Gong","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102954_bib0032","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102954_bib0033","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0034","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102954_bib0035","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ajh.27041","article-title":"Impact of MRD on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph+ ALL: a retrospective nationwide study","volume":"98","author":"Hirabayashi","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0036","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1007\/s00277-024-05944-0","article-title":"Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia","volume":"103","author":"Sugita","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0037","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2015.98","article-title":"Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia","volume":"29","author":"Ruggeri","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102954_bib0038","doi-asserted-by":"crossref","first-page":"710.e1","DOI":"10.1016\/j.jtct.2022.07.006","volume":"28","author":"Ruggeri","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102954_bib0039","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bjh.18530","article-title":"Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non-remission acute myeloid leukaemia: a nationwide retrospective study","volume":"201","author":"Matsuda","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0040","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/bloodadvances.2016002386","article-title":"Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1","volume":"1","author":"Versluis","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102954_bib0041","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102954_bib0042","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41409-023-02142-w","article-title":"Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide","volume":"59","author":"Shimomura","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102954_bib0043","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/bloodadvances.2021004462","article-title":"Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning","volume":"5","author":"Wagner","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2026.102954_bib0044","doi-asserted-by":"crossref","first-page":"365.e1","DOI":"10.1016\/j.jtct.2023.03.001","article-title":"Effect of graft-versus-host disease on post-transplantation outcomes following single cord blood transplantation compared with haploidentical transplantation with post-transplantation cyclophosphamide for adult acute myeloid leukemia","volume":"29","author":"Konuma","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102954_bib0045","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1182\/blood-2003-04-1288","article-title":"Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis","volume":"102","author":"Michel","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102954_bib0046","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/leu.2015.243","article-title":"Unrelated cord blood transplantation for childhood acute myelogenous leukemia: the influence of cytogenetic risk group stratification","volume":"30","author":"Michel","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102954_bib0047","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3324\/haematol.2018.208454","article-title":"How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?","volume":"104","author":"Short","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2026.102954_bib0048","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102954_bib0049","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","article-title":"Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study","volume":"27","author":"Cilloni","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102954_bib0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12185-015-1882-1","article-title":"Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood","volume":"103","author":"Kitamura","year":"2016","journal-title":"Int J Hematol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926009151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926009151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:23:30Z","timestamp":1794572610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926009151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1465324926009151"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102954","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Haploidentical transplantation versus umbilical cord blood transplantation in acute myeloid leukemia with measurable residual disease","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102954"}}